Product Name: SIK (179-185) pT182
Product Number: PE-04APP99
Size: 200 µg      Price:42.00
1 mg      $US84.00
5 mg      185.00
Peptide Name: SIK (179-185) pT182

Product Use: Services as a blocking peptide for use with the SIK-pT182 rabbit polyclonal antibody (Cat. No.: AB-PK812) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T182 phosphorylation is predicted to be stimulatory for phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: PLS-pT-WCG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1016.08 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: SIK - pT182 phosphosite-specific antibody (Cat. No.: AB-PK812)

Scientific Background: SIK (SNF1LK) is a protein-serine/threonine kinase of the CAMK group and CAMKL family. It can mediate gluconeogenesis, lipogenesis, cell cycle regulation, muscle differentiation, muscle growth, and tumour suppression. Substrates of SIK can include SREBF1, HDAC5, PPME1, TORC1/CRTC1, HDAC4, and TORC2/CRTC2. Phosphorylation at S186 increases phosphotransferase activity and induces interaction with 14-3-3. It is also activated by phosphorylation on T182 by STK11 in complex with STE20-related adapter-alpha (STRAD alpha) pseudo kinase and CAB39. SIK may be a tumour requiring protein (TRP). The loss of SIK1 has been correlated with poor prognosis for individuals suffering from breast cancer. Kinase phosphotransferase activity can be decreased without affecting autophosphorylation levels of SIK through either a S135A, or a S209A, or a S248A mutation. LKB1/LKB1-mediated phosphorylation and activation of SIK can be inhibited through a T182A mutation in SIK. Partial inhibition of phosphorylation and of kinase phosphotransferase activity has been observed with the S186A/D/C/G mutation. Abrogation of autophosphorylation and kinase phosphotransferase activity can occur with a S186T mutation.